|
Yale SPORE in Skin Cancer
|
2P50CA121974-06A1
|
$2,300,000
|
$276,000
|
HALABAN, RUTH
|
YALE UNIVERSITY
|
|
YALE COMPREHENSIVE CANCER CENTER
|
3P30CA016359-33S3
|
$600,000
|
$90,000
|
Lynch, Thomas
|
YALE UNIVERSITY
|
|
YALE COMPREHENSIVE CANCER CENTER
|
3P30CA016359-33S4
|
$75,000
|
$11,250
|
Lynch, Thomas
|
YALE UNIVERSITY
|
|
Wnt5a and TGF-beta in mammary development and cancer
|
5R01CA126942-04
|
$291,849
|
$145,925
|
Serra, Rosa
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Wnt antagonist genes in kidney tumor progression and metastasis
|
5R01CA130860-05
|
$601,339
|
$601,339
|
DAHIYA, RAJVIR
|
NORTHERN CALIFORNIA INSTITUTE RES & EDUC
|
|
Winship Cancer Institute Cancer Center Support Grant
|
2P30CA138292-04
|
$1,492,676
|
$223,901
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-04S1
|
$74,993
|
$11,249
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-04S2
|
$149,680
|
$22,452
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Whole-Body PET/CT Assessment of Tumor Perfusion Using Generator-Produced 62Cu
|
5R01CA140299-04
|
$416,149
|
$208,075
|
Fletcher, James
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Vitamin D status, Gene Polymorphism and Breast Cancer Progression/Prognosis
|
5R03CA156648-02
|
$78,000
|
$39,000
|
SHU, XIAO-Ou
|
VANDERBILT UNIVERSITY MED CTR
|
|
Vitamin D in Prostate Cancer: Tumor Vasculature Effects
|
5R01CA095045-10
|
$276,360
|
$138,180
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Vitamin D Analogs for Chemoprevention of Prostate CAncer
|
5R01CA095367-08
|
$374,697
|
$93,674
|
FOSTER, BARBARA
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
3R01CA109860-08S1
|
$75,516
|
$75,516
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
5R01CA109860-08
|
$328,499
|
$328,499
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
Vesicular stomatitis VSVrp30 selectively destroys human metastatic melanoma
|
1R01CA161048-01A1
|
$344,191
|
$344,191
|
VAN DEN POL, ANTHONY
|
YALE UNIVERSITY
|
|
Vermont PROSPR Research Center (VPRC)
|
5U54CA163303-02
|
$944,888
|
$47,244
|
Sprague, Brian
|
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
|
|
VEGFs in tumor lymphatic metastasis
|
5R01CA142262-04
|
$452,526
|
$452,526
|
DVORAK, HAROLD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
VEGF Signaling in Mammary Tumorigenesis
|
1R01CA168464-01A1
|
$344,450
|
$172,225
|
Mercurio, Arthur
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
VEGF Gene Amplification/Haplotype as Biomarkers for Bevacizumab in Breast Cancer
|
5R01CA155311-02
|
$322,642
|
$322,642
|
Schneider, Bryan
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
VEGF and PDGF in angiogenesis and tumor progression
|
5R37CA050286-24
|
$459,245
|
$459,245
|
CHERESH, DAVID
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
|
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy
|
5R01CA103986-08
|
$246,403
|
$246,403
|
Kleinerman, Eugenie
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Vascular mechanisms regulating breast cancer brain metastasis
|
1R01CA170140-01
|
$369,198
|
$369,198
|
ELICEIRI, BRIAN
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
|
Vascular Biology in Cancer
|
ZIABC011390
|
$1,292,548
|
$387,764
|
Lin, Pengnian Charles
|
CCR (NCI)
|
|
Vanderbilt In Vivo Cellular and Molecular Imaging Center
|
5P50CA128323-05
|
$1,070,400
|
$107,040
|
Gore, John
|
VANDERBILT UNIVERSITY MED CTR
|
|
Validation of Genomic Targets in Melanoma
|
5R01CA114337-08
|
$351,145
|
$351,145
|
KASHANI-SABET, MOHAMMED
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
|
1P01CA154291-01A1
|
$1,651,535
|
$346,822
|
BIGNER, DARELL
|
DUKE UNIVERSITY
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-38S3
|
$4,555,705
|
$592,242
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-38S4
|
$74,854
|
$9,731
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-38S5
|
$139,989
|
$18,199
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Utilizing proteoglycan biology to develop a novel treatment for brain cancers
|
1F31CA168198-01
|
$31,217
|
$7,804
|
Raman, Karthik
|
UNIVERSITY OF UTAH
|
|
Uses of GEM models for Translational Cancer Research
|
7U01CA141508-04
|
$760,324
|
$760,324
|
CHIN, LYNDA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Use of Mouse Models of Human Rhabdomyosarcoma to Study Progression to Metastasis
|
ZIABC010871
|
$58,062
|
$40,644
|
Merlino, Glenn
|
CCR (NCI)
|
|
Use of aAPC for Melanoma Adoptive Immunotherapy
|
5R01CA108835-07
|
$318,780
|
$318,780
|
SCHNECK, JONATHAN
|
JOHNS HOPKINS UNIVERSITY
|
|
USE AND OUTCOMES OF INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN PROSTATE CANCER
|
1R03CA167454-01
|
$77,500
|
$77,500
|
Tsai, Huei-Ting
|
GEORGETOWN UNIVERSITY
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-37S1
|
$50,000
|
$4,500
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-37S2
|
$246,000
|
$22,140
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-37S3
|
$74,999
|
$6,750
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
5P30CA014089-37
|
$6,285,726
|
$565,715
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
UPRCCC/MDACC: Partnership for Excellence in Cancer Research
|
3U54CA096297-10S1
|
$202,000
|
$68,680
|
FRONTERA, WALTER
|
UNIVERSITY OF PUERTO RICO MED SCIENCES
|
|
UPRCCC/MDACC: Partnership for Excellence in Cancer Research
|
3U54CA096297-10S2
|
$74,686
|
$25,393
|
FRONTERA, WALTER
|
UNIVERSITY OF PUERTO RICO MED SCIENCES
|
|
UPRCCC/MDACC: Partnership for Excellence in Cancer Research
|
5U54CA096297-10
|
$1,679,075
|
$570,886
|
LOPEZ-ENRIQUEZ, REYNOLD
|
UNIVERSITY OF PUERTO RICO MED SCIENCES
|
|
UPRCCC/MDACC: Partnership for Excellence in Cancer Research
|
5U54CA096300-10
|
$1,206,053
|
$410,058
|
DUBOIS, RAYMOND
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
UNMC Eppley Cancer Center Support Grant
|
3P30CA036727-26S1
|
$74,440
|
$28,287
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
UNMC Eppley Cancer Center Support Grant
|
5P30CA036727-26
|
$1,427,680
|
$542,518
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
University of New Mexico Cancer Center Support
|
3P30CA118100-08S1
|
$140,000
|
$2,800
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of New Mexico Cancer Center Support
|
3P30CA118100-08S2
|
$75,000
|
$1,500
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of New Mexico Cancer Center Support
|
5P30CA118100-08
|
$1,934,104
|
$38,682
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
2P30CA046592-24
|
$5,694,947
|
$968,141
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-24S1
|
$49,948
|
$8,491
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-24S2
|
$74,872
|
$12,728
|
WICHA, MAX
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
Total relevant funding to Metastasis for this search: $396,456,505
|